ClinicalTrials.gov
ClinicalTrials.gov Menu

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01545076
Recruitment Status : Completed
First Posted : March 6, 2012
Results First Posted : July 4, 2018
Last Update Posted : July 4, 2018
Sponsor:
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
CSL Behring

March 1, 2012
March 6, 2012
April 9, 2018
July 4, 2018
July 4, 2018
March 2012
September 2016   (Final data collection date for primary outcome measure)
Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period [ Time Frame: Up to 25 weeks ]
Relapse is defined as an increase of at least 1 INCAT score point (except for the increase from 0 to 1 in the upper limb score). The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 ("No upper limb problems") to 5 ("Inability to use either arm for any purposeful movement"), and scores for leg disability range from 0 ("Walking not affected") to 5 ("Restricted to wheelchair, unable to stand and walk a few steps with help"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the "adjusted" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.
Percentage (%) of subjects who relapse during the SC treatment period [ Time Frame: 24 weeks ]
Relapse is defined as an increase of at least 1 INCAT score point (except for the increase from 0 to 1 in the upper limb score).
Complete list of historical versions of study NCT01545076 on ClinicalTrials.gov Archive Site
  • Change in Inflammatory Neuropathy Cause and Treatment (INCAT) Scores During the SC Treatment Period [ Time Frame: Baseline and up to 25 weeks ]
    The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 ("No upper limb problems") to 5 ("Inability to use either arm for any purposeful movement"), and scores for leg disability range from 0 ("Walking not affected") to 5 ("Restricted to wheelchair, unable to stand and walk a few steps with help"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the "adjusted" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.
  • Median Change From Baseline in the Mean Grip Strength Scores of the Dominant Hand During the SC Treatment Period [ Time Frame: Baseline and up to 25 weeks ]
    The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.
  • Change in the Medical Research Council (MRC) Sum Scores During the SC Treatment Period [ Time Frame: Baseline and up to 25 weeks ]
    An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).
  • Change in Rasch-built Overall Disability Scale (R-ODS) Scores During the SC Treatment Period [ Time Frame: Baseline and up to 25 weeks ]
    The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).
  • Time to CIDP Relapse or Withdrawal Due to Any Other Reason During the SC Treatment Period [ Time Frame: Up to 25 weeks ]
  • Number of Adverse Events Per IgPro20 Infusion During the SC Treatment Period [ Time Frame: Up to 28 weeks ]
  • Number of Subjects With Adverse Events During the SC Treatment Period [ Time Frame: Up to 28 weeks ]
  • Percentage of Subjects With Adverse Events During the SC Treatment Period [ Time Frame: Up to 28 weeks ]
  • Time to Improvement During IgPro10 Re-stabilization Therapy [ Time Frame: Up to 13 weeks ]
    Improvement is defined as an INCAT score decrease by 1 point (except for the decrease from 1 to 0 in the upper limb score), R-ODS improvement by at least 4 points, Mean Grip strength improvement by at least 8 kPa in one hand, or MRC Sum score >=3.
  • Change in Mean Grip Strength During IgPro10 Re-stabilization Therapy [ Time Frame: Reference visit and up to 13 weeks ]
    The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.
  • Change in MRC Sum Score During IgPro10 Re-stabilization Therapy [ Time Frame: Reference visit and up to 13 weeks ]
    An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).
  • Change in R-ODS During IgPro10 Re-stabilization Therapy [ Time Frame: Reference visit and up to 13 weeks ]
    The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).
  • Change in INCAT During IgPro10 Re-stabilization Therapy [ Time Frame: Reference visit and up to 13 weeks ]
    The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 ("No upper limb problems") to 5 ("Inability to use either arm for any purposeful movement"), and scores for leg disability range from 0 ("Walking not affected") to 5 ("Restricted to wheelchair, unable to stand and walk a few steps with help"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the "adjusted" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.
  • Number of Adverse Events Per IgPro10 Infusion During Re-stabilization Therapy [ Time Frame: Up to 13 weeks ]
  • Number of Subjects With Adverse Events During IgPro10 Re-stabilization Therapy [ Time Frame: Up to 13 weeks ]
  • Percent of Subjects With Adverse Events During IgPro10 Re-stabilization Therapy [ Time Frame: Up to 13 weeks ]
  • Time to Improvement After CIDP Relapse During IgPro10 Rescue Therapy [ Time Frame: Up to 13 weeks ]
    Improvement is defined as a decrease in INCAT score (except for the decrease from 1 to 0 in the upper limb score) back to or below the baseline score..The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 ("No upper limb problems") to 5 ("Inability to use either arm for any purposeful movement"), and scores for leg disability range from 0 ("Walking not affected") to 5 ("Restricted to wheelchair, unable to stand and walk a few steps with help"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the "adjusted" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.
  • Number of Adverse Events Per IgPro10 Infusion During Rescue Therapy [ Time Frame: Up to 13 weeks ]
  • Number of Subjects With Adverse Events During IgPro10 Rescue Therapy [ Time Frame: Up to 13 weeks ]
  • Percent of Subjects With Adverse Events During IgPro10 Rescue Therapy [ Time Frame: Up to 13 weeks ]
  • Change in Mean Grip Strength During IgPro10 Rescue Therapy [ Time Frame: Before first rescue IgPro10 infusion and up to 13 weeks ]
    The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.
  • Change in MRC Sum Score During IgPro10 Rescue Therapy [ Time Frame: Before first rescue IgPro10 infusion and up to 13 weeks ]
    An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).
  • Change in R-ODS During IgPro10 Rescue Therapy [ Time Frame: Before first rescue IgPro10 infusion and up to 13 weeks ]
    The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).
  • Change in INCAT During IgPro10 Rescue Therapy [ Time Frame: Before first rescue IgPro10 infusion and up to 13 weeks ]
    The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 ("No upper limb problems") to 5 ("Inability to use either arm for any purposeful movement"), and scores for leg disability range from 0 ("Walking not affected") to 5 ("Restricted to wheelchair, unable to stand and walk a few steps with help"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the "adjusted" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.
  • Change in mean Inflammatory Neuropathy Cause and Treatment (INCAT) scores during the SC treatment period [ Time Frame: SC week 1, SC week 25 ]
  • Change in mean maximum grip strength scores during the SC treatment period [ Time Frame: SC week 1, SC week 25 ]
  • Change in mean Medical Research Council (MRC) sum scores during the SC treatment period [ Time Frame: SC week 1, SC week 25 ]
  • Time to CIDP relapse [ Time Frame: up to 24 weeks ]
  • Rate of adverse events per SC infusion [ Time Frame: 24 weeks ]
  • Number of Subjects With Adverse Events During the SC Treatment Period [ Time Frame: 24 weeks ]
  • Percentage of Subjects With Adverse Events During the SC Treatment Period [ Time Frame: 24 weeks ]
Not Provided
Not Provided
 
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of patients with CIDP.

Patients who received at lease 1 dose of intravenous immunoglobulin (IVIG) within 8 weeks before screening will be assessed during 4 separate study periods. Patients first undergo a Screening Period, followed by an IgG Dependency Test Period of up to 12 weeks to test for ongoing need of IgG. Those patients experiencing CIDP relapse during this test period will be administered a standardized IVIG regimen during an IVIG Re-stabilization Period. Patients with improved and maintained adjusted inflammatory neuropathy cause and treatment scale (INCAT) in the IVIG Re-stabilization Period will continue to the SC Treatment Period of the study. Patients entering the 24 week SC Treatment Period will be randomized to receive weekly infusions of 1 of 2 IgPro20 doses (0.2 or 0.4 g/kg body weight) or placebo.

The overall study duration is up to 52 weeks. Clinical outcomes will be assessed by the Inflammatory Neuropathy Cause and Treatment (INCAT) score, maximum grip strength, the Medical Research Council (MRC) sum score, the Rasch-built Overall Disability Scale (R-ODS), and electrophysiological evaluations.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyradiculoneuropathy
  • Biological: IgPro20 (low dose)

    20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:

    0.2 g/kg body weight (low dose arm)

    Other Name: Hizentra
  • Biological: Placebo
    2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
  • Biological: IgPro10
    10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
  • Biological: IgPro20 (high dose)

    20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:

    0.4 g/kg body weight (high dose arm)

    Other Name: Hizentra
  • Experimental: IgPro20 low dose
    Interventions:
    • Biological: IgPro20 (low dose)
    • Biological: IgPro10
  • Experimental: IgPro20 high dose
    Interventions:
    • Biological: IgPro10
    • Biological: IgPro20 (high dose)
  • Placebo Comparator: Placebo
    Interventions:
    • Biological: Placebo
    • Biological: IgPro10

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
208
250
September 2016
September 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Definite or probable CIDP according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010.
  • An IVIG treatment during the last 8 weeks prior to enrollment.
  • Age ≥18 years.
  • Written informed consent for study participation obtained before undergoing any study-specific procedures.

Exclusion Criteria:

  • Any polyneuropathy of other causes
  • Any other disease (mainly neurological or chronic orthopedic) that has caused neurological symptoms or may interfere with treatment or outcome assessments
  • Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study
  • History of thrombotic episodes within the 2 years prior to enrolment
  • Known allergic or other severe reactions to blood products including intolerability to previous IVIG
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Canada,   Czechia,   Estonia,   Finland,   France,   Germany,   Israel,   Italy,   Japan,   Netherlands,   Poland,   Spain,   United Kingdom,   United States
Austria,   Czech Republic
 
NCT01545076
IgPro20_3003
Yes
Not Provided
Not Provided
CSL Behring
CSL Behring
ICON Clinical Research
Principal Investigator: Prof. Dr. Ivo N. van Schaik Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CSL Behring
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP